Chat with us
Research Assistance
Online
  • Please enter your first name.

Middle East & Africa Microbiome Therapeutics Market Size & Outlook

The microbiome therapeutics market in Middle East & Africa is expected to reach a projected revenue of US$ 11.0 million by 2030. A compound annual growth rate of 16.6% is expected of Middle East & Africa microbiome therapeutics market from 2023 to 2030.

  • Pharmaceuticals
    • Metabolic Disorders Treatment
      • Microbiome Therapeutics Market Outlook
Revenue, 2022 (US$M)
$3.2
Forecast, 2030 (US$M)
$11.0
CAGR, 2023 - 2030
16.6%
Report Coverage
Middle East & Africa

Middle East Africa Microbiome Therapeutics Market, 2018-2030 (US$M)

Middle East Africa Microbiome Therapeutics Market, 2018-2030 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Prism AI by Grand View ResearchFree to try

Ask a question about the microbiome therapeutics market

Every figure cited from GVR research

MEA microbiome therapeutics market highlights

  • The MEA microbiome therapeutics market generated a revenue of USD 3.2 million in 2022.
  • The market is expected to grow at a CAGR of 16.6% from 2023 to 2030.
  • In terms of segment, c. difficile was the largest revenue generating application in 2022.
  • C. difficile is the most lucrative application segment registering the fastest growth during the forecast period.
  • Country-wise, South Africa is expected to register the highest CAGR from 2023 to 2030.


MEA data book summary

Market revenue in 2022USD 3.2 million
Market revenue in 2030USD 11.0 million
Growth rate16.6% (CAGR from 2022 to 2030)
Largest segmentC. difficile
Fastest growing segmentC. difficile
Historical data covered2018 - 2021
Base year for estimation2022
Forecast period covered2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationC. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes
Key market players worldwideFinch Therapeutics Group Inc, Vedanta


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.4% of the global microbiome therapeutics market in 2022.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • North America is the fastest growing regional market and is projected to reach USD 901.1 million by 2030.

The Middle East and Africa (MEA) region is expected to grow at a moderately high growth rate in the coming years due to increasing awareness about the importance of gut health and the potential benefits of microbiome-based treatments.

The market is driven by factors such as the growing incidence of chronic diseases, increasing demand for personalized medicine, and advancements in microbiome research. In recent years, there has been a significant increase in the number of clinical trials and research studies aimed at exploring the therapeutic potential of the microbiome.

This has led to the development of various microbiome-based products and Fecal Microbiota Transplantation (FMT) products. Moreover, the rising demand for natural and noninvasive treatments, combined with the growing preference for personalized medicine, is expected to drive the growth of microbiome therapeutics market in MEA.

No credit card required*

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Microbiome Therapeutics Market Companies

NameProfile# EmployeesHQWebsite
VedantaView profile 10001+Hyderabad, Andhra Pradesh, India, Asiawww.vedantalimited.com/
Finch Therapeutics Group IncView profile 175 State Street, Suite 100, Boston, MA, United States, 02109www.finchtherapeutics.com
4D PharmaView profile 101-250Aberdeen, Aberdeen City, United Kingdom, Europewww.4dpharmaplc.com
Seres Therapeutics IncView profile 233101 Cambridgepark Drive, Cambridge, MA, United States, 02140www.serestherapeutics.com
Locus BiosciencesView profile 51-100Morrisville, North Carolina, United States, North Americawww.locus-bio.com/
ENTEROMEView profile 51-100Paris, Ile-de-France, France, Europewww.enterome.com
IntralytixView profile 11-50Baltimore, Maryland, United States, North Americawww.intralytix.com/
MicrobioticaView profile 11-50Cambridge, Cambridgeshire, United Kingdom, Europewww.microbiotica.com/
Second GenomeView profile 11-50San Francisco, California, United States, North Americawww.secondgenome.com
Vedanta BiosciencesView profile 101-250Cambridge, Massachusetts, United States, North Americawww.vedantabio.com

Middle East & Africa Microbiome Therapeutics Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Microbiome Therapeutics Market Outlook will help companies and investors design strategic landscapes.


C. Difficile was the largest segment with a revenue share of 84.38% in 2022.

Horizon Databook has segmented the Middle East & Africa microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.




The Middle East and Africa (MEA) region is expected to grow at a moderately high growth rate in the coming years due to increasing awareness about the importance of gut health and the potential benefits of microbiome-based treatments.

The market is driven by factors such as the growing incidence of chronic diseases, increasing demand for personalized medicine, and advancements in microbiome research. In recent years, there has been a significant increase in the number of clinical trials and research studies aimed at exploring the therapeutic potential of the microbiome.

This has led to the development of various microbiome-based products and Fecal Microbiota Transplantation (FMT) products. Moreover, the rising demand for natural and noninvasive treatments, combined with the growing preference for personalized medicine, is expected to drive the growth of microbiome therapeutics market in MEA.

  • Middle East & Africa Microbiome Therapeutics Market Application Outlook (Revenue, USD Million , 2018-2030)
    • Crohns disease
    • C. difficile
    • Inflammatory Bowel Disease
    • Others
    • Diabetes
  • Middle East & Africa Microbiome Therapeutics Market Type Outlook (Revenue, USD Million , 2018-2030)
    • Microbiome Drugs
    • FMT

Reasons to subscribe to Microbiome Therapeutics Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Microbiome Therapeutics Market Outlook databook

  • Our clientele includes a mix of Microbiome Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Microbiome Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Microbiome Therapeutics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Middle East Africa Microbiome Therapeutics Market, 2018-2030 (US$M)

No Access Stack Chart

MEA microbiome therapeutics market statistics, by application, 2018-2030 (US$M)

No Access Pie Chart

MEA microbiome therapeutics market statistics, by country, 2018-2030 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more